Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tLNP-mRNA
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
tLNP-mRNA is an investigational *in vivo* mRNA-based immunotherapy developed by West China Hospital of Sichuan University. The therapy utilizes T cell-targeted lipid nanoparticles (tLNPs) to deliver mRNA directly to T cells within the patient's body. Once internalized, the mRNA is translated by the T cells to express therapeutic proteins, such as chimeric antigen receptors (CARs), effectively reprogramming the T cells *in vivo* to recognize and eliminate malignant cells. This approach is designed to circumvent the logistical complexities and high costs associated with traditional *ex vivo* CAR-T cell manufacturing. It is currently being evaluated in a Phase 1 clinical trial for patients with relapsed or refractory multiple myeloma.
- Other names
- T cell-targeted tLNP-mRNAT cell-targeted lipid nanoparticle-mRNA
02
Targets
SIRPA (Signal-regulatory protein alpha)CD5 (T-cell surface glycoprotein CD5)
Beyond the preview
Go deeper on tLNP-mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tLNP-mRNA.